← 홈

ADC

1,068개 · ADC 1068 · Antibody 5456 · CGT 2744 · 다음 갱신 D-13 · 마지막 7월 13일

인기최근 업데이트큐레이션임상 많은갱신 필요ORR최신Phase 3FDA승인프로그램 1,068개
ADCBiologicValerio TherapeuticsPhase 3

Dexrazoxane Hydrochloride (Dexrazoxane Hydrochloride)

Cardiac Toxicity; Inflammatory Breast Cancer · Acute Myeloid Leukemia

#AcuteMyeloidLeukemia#ADC#Phase3#항체약물접합체#antibody-drug-conjugate+4
효능 ORR 78.6%임상시험 47상태 RECRUITING
ADCBiologicPfizerPhase 3

Iberdomide (Iberdomide)

Multiple Myeloma · FRα

#FR#ADC#Phase3#항체약물접합체#antibody-drug-conjugate+3
효능 ORR 92.9%임상시험 47상태 RECRUITING
ADCBiologicAstellasVedotin Plus Pembrolizumab …Phase 3

EV/P (enfortumab vedotin and pembrolizumab, enfortumab vedotin and pembrolizumab (EV/P))

Advanced Bladder Cancer · Advanced Bladder Cancer

#AdvancedBladderCancer#ADC#Phase3#항체약물접합체#antibody-drug-conjugate+3
효능 ORR 15.6%임상시험 47상태 RECRUITING
ADCBiologicPfizerderuxtecan showed encouragi…Phase 1

Dacomitinib (Dacomitinib)

Non-Small Cell Lung Cancer · FRα

#FR#ADC#Phase1#항체약물접합체#antibody-drug-conjugate+4
효능 ORR 75.3%임상시험 46상태 DISCONTINUED
ADCBiologicCanadian Cancer Trials Groupvedotin, a monoclonal antib…Phase 2

Adavosertib (Adavosertib)

Prostate Cancer · FRα

#FR#ADC#Phase2#항체약물접합체#antibody-drug-conjugate+3
효능 ORR 66.7%임상시험 45상태 RECRUITING
ADCBiologicFondazione per la Medicina Pers…Phase 2

Pemigatinib (Pemigatinib)

Breast Cancer; Gastrointestinal Cancer · Breast Cancer

#BreastCancer#ADC#Phase2#항체약물접합체#antibody-drug-conjugate+2
효능 ORR 37%임상시험 45상태 ACTIVE
ADCBiologicSichuan Baili Pharmaceutical Co…viaPhase 2

BL-B01D1 (BL-B01D1)

Rare Malignant Neoplasm; Advanced Solid Tumors · Rare Malignant Neoplasm

#RareMalignantNeoplasm#ADC#Phase2#항체약물접합체#antibody-drug-conjugate+4
임상시험 44상태 RECRUITING
ADCBiologicAstraZenecaDeruxtecan-Dlnk Quantificat…Approved

Dato-DXd (Datopotamab Deruxtecan, Datopotamab Deruxtecan (Dato-DXd))

Advanced Solid Malignancies · Carcinoma, Non-Small-Cell Lung

#CarcinomaNon-Small-CellLung#ADC#Approved#항체약물접합체#antibody-drug-conjugate+4
효능 ORR 79%임상시험 43상태 RECRUITING
ADCBiologicOHSU Knight Cancer InstitutePhase 1

Enasidenib (Enasidenib)

Accelerated Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive; Anatomic Stage IV Breast Cancer AJCC v8 · Acute Myeloid Leukemia

#AcuteMyeloidLeukemia#ADC#Phase1#항체약물접합체#antibody-drug-conjugate+5
효능 ORR 73.5%임상시험 43상태 DISCONTINUED
ADCBiologicEMD Serono Research & Developme…Phase 3

M7824 (M7824)

Non-small Cell Lung Cancer · HER2

#HER2#ADC#Phase3#항체약물접합체#antibody-drug-conjugate+3
효능 ORR 62.5%임상시험 43상태 DISCONTINUED
ADCBiologicSuzhou Suncadia Biopharmaceutic…Vedotin in Transplant-Ineli…Phase 2

R-GemOx (R-GemOx)

Relapsed and Refractory DLBCL · FRα

#FR#ADC#Phase2#항체약물접합체#antibody-drug-conjugate+4
효능 ORR 69.7%임상시험 43상태 RECRUITING
ADCBiologicmedac GmbHPhase 2

Asparaginase Erwinia chrysanthemi (Asparaginase Erwinia chrysanthemi)

B Acute Lymphoblastic Leukemia, Philadelphia Chromosome Negative; T Acute Lymphoblastic Leukemia · Acute Myeloid Leukemia

#AcuteMyeloidLeukemia#ADC#Phase2#항체약물접합체#antibody-drug-conjugate+4
효능 ORR 18%임상시험 42상태 RECRUITING
ADCBiologicInstitut National de la Santé E…Phase 3

Ceritinib (Ceritinib)

Soft Tissue Sarcoma · CD30

#CD30#ADC#Phase3#항체약물접합체#antibody-drug-conjugate+3
효능 ORR 100%임상시험 42상태 ACTIVE
ADCBiologicCancer Research UKvedotin, and venetoclax dem…Phase 3

Entrectinib (Entrectinib)

Haematological Malignancy; Solid Tumour · Advanced Breast Carcinoma

#AdvancedBreastCarcinoma#ADC#Phase3#항체약물접합체#antibody-drug-conjugate+5
효능 ORR 11.5%임상시험 42상태 DISCONTINUED
ADCBiologicGileadgovitecan-hziy (Trodelvy), …Phase 2

sacituzumab govitecan (Trodelvy, Sacituzumab Govitecan-hziy)

Metastatic Urothelial Cancer · Metastatic Urothelial Cancer

#MetastaticUrothelialCancer#ADC#Phase2#항체약물접합체#antibody-drug-conjugate+3
효능 ORR 34.3%임상시험 42상태 RECRUITING
ADCBiologicExelixisPhase 2

Cabozantinib S-malate (Cabozantinib S-malate)

Differentiated Thyroid Gland Carcinoma; Follicular Variant Thyroid Gland Papillary Carcinoma · Infiltrating Bladder Urothelial Carcinom

#InfiltratingBladderUrothelialCar#ADC#Phase2#항체약물접합체#antibody-drug-conjugate+3
효능 ORR 25%임상시험 41상태 RECRUITING
ADCBiologicAstraZenecadeliveryPhase 3

Ceralasertib (Ceralasertib)

Lung Non-Small Cell Carcinoma; Stage II Lung Cancer AJCC v8 · Non-Small Cell Lung Cancer

#Non-SmallCellLungCancer#ADC#Phase3#항체약물접합체#antibody-drug-conjugate+5
효능 ORR 19%임상시험 41상태 RECRUITING
ADCBiologicMerck Sharp & Dohme LLCDeruxtecan in Patients With…Phase 2

I-DXd (Ifinatamab Deruxtecan, Ifinatamab Deruxtecan (I-DXd))

Carcinoma, Non-Small-Cell Lung · Small-Cell Lung Cancer

#Small-CellLungCancer#ADC#Phase2#항체약물접합체#antibody-drug-conjugate+5
임상시험 41상태 RECRUITING
ADCBiologicCanadian Cancer Trials GroupPhase 2

Savolitinib (Savolitinib)

Prostate Cancer · Non-Small Cell Lung Cancer

#Non-SmallCellLungCancer#ADC#Phase2#항체약물접합체#antibody-drug-conjugate+2
효능 ORR 57.1%임상시험 41상태 RECRUITING
ADCBiologicMillennium Pharmaceuticals, Inc.Vedotin or Other Standard T…Phase 3

Bexarotene (Bexarotene)

Primary Cutaneous Anaplastic Large Cell Lymphoma; Mycosis Fungoides · Primary Cutaneous Anaplastic Large Cell

#PrimaryCutaneousAnaplasticLargeC#ADC#Phase3#항체약물접합체#antibody-drug-conjugate+4
효능 ORR 54.7%임상시험 40상태 ACTIVE

13 / 54 페이지

← 이전다음 →